Alnylam Pharmaceuticals Raw materials decreased by 17.6% to $11.69M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 50.0%, from $23.40M to $11.69M. Over 5 years (FY 2020 to FY 2025), Raw materials shows a downward trend with a -25.9% CAGR.
An increase may signal anticipation of higher production demand or a hedge against rising commodity costs, while a decrease could indicate supply chain efficiency or production slowdowns.
This represents the cost of basic materials and components that have not yet been processed into finished goods. It is a...
Varies by industry; essential for manufacturing and food production companies.
other_inventory_raw_materials| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $54.34M | $65.16M | $14.75M | $20.37M | $19.14M | $17.72M | $22.32M | $22.88M | $17.45M | $20.12M | $23.35M | $25.40M | $26.02M | $22.37M | $23.97M | $23.40M | $22.87M | $22.25M | $14.18M | $11.69M |
| QoQ Change | — | +19.9% | -77.4% | +38.1% | -6.0% | -7.4% | +25.9% | +2.5% | -23.7% | +15.3% | +16.0% | +8.8% | +2.4% | -14.1% | +7.2% | -2.4% | -2.3% | -2.7% | -36.3% | -17.6% |
| YoY Change | — | — | — | — | -64.8% | -72.8% | +51.2% | +12.3% | -8.8% | +13.6% | +4.6% | +11.0% | +49.1% | +11.2% | +2.7% | -7.9% | -12.1% | -0.5% | -40.8% | -50.0% |